Annual report pursuant to Section 13 and 15(d)

Segments

v3.3.1.900
Segments
12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Segments

17.

Segments

We report information about our operating segments using the “management approach” in accordance with current accounting standards.  This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance.  Our reportable segments are identified based on differences in products, services and markets served.  There were no inter-segment sales.  Prior to 2015, our products and development programs were all related to diagnostic substances.  Our majority-owned subsidiary, Macrophage Therapeutics, Inc., was formed and received initial funding during the first quarter of 2015, which resulted in a re-evaluation of the Company's segment determination.  We now manage our business based on two primary types of drug products: (i) diagnostic substances, including Lymphoseek and other diagnostic applications of our Manocept platform, our R-NAV subsidiary, NAV4694 and NAV5001 (license terminated in April 2015), and (ii) therapeutic development programs, including therapeutic applications of our Manocept platform and all development programs undertaken by Macrophage Therapeutics, Inc.

The information in the following tables is derived directly from each reportable segment’s financial reporting.

 

Year Ended December 31, 2015

 

Diagnostics

 

 

Therapeutics

 

 

Corporate

 

 

Total

 

Lymphoseek sales revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States (1)

 

$

10,229,659

 

 

$

 

 

$

 

 

$

10,229,659

 

International

 

 

24,693

 

 

 

 

 

 

 

 

 

24,693

 

Lymphoseek license revenue

 

 

1,133,333

 

 

 

 

 

 

 

 

 

1,133,333

 

Grant and other revenue

 

 

1,861,622

 

 

 

 

 

 

 

 

 

1,861,622

 

Total revenue

 

 

13,249,307

 

 

 

 

 

 

 

 

 

13,249,307

 

Cost of goods sold, excluding depreciation and amortization

 

 

1,654,800

 

 

 

 

 

 

 

 

 

1,654,800

 

Research and development expenses,

   excluding depreciation and amortization

 

 

12,046,221

 

 

 

730,895

 

 

 

 

 

 

12,777,116

 

Selling, general and administrative expenses,

   excluding depreciation and amortization (2)

 

 

5,852,214

 

 

 

123,884

 

 

 

10,820,392

 

 

 

16,796,490

 

Depreciation and amortization (3)

 

 

281,314

 

 

 

 

 

 

290,105

 

 

 

571,419

 

Loss from operations (4)

 

 

(6,585,242

)

 

 

(854,779

)

 

 

(11,110,497

)

 

 

(18,550,518

)

Other income (expense), excluding

   equity in the loss of R-NAV, LLC (5)

 

 

 

 

 

 

 

 

(9,902,424

)

 

 

(9,902,424

)

Equity in the loss of R-NAV, LLC

 

 

 

 

 

 

 

 

(305,253

)

 

 

(305,253

)

Benefit from income taxes

 

 

 

 

 

 

 

 

436,051

 

 

 

436,051

 

Net loss from continuing operations

 

 

(6,585,242

)

 

 

(854,779

)

 

 

(20,882,123

)

 

 

(28,322,144

)

Income from discontinued operations, net of tax effect (6)

 

 

 

 

 

 

 

 

758,609

 

 

 

758,609

 

Net loss

 

 

(6,585,242

)

 

 

(854,779

)

 

 

(20,123,514

)

 

 

(27,563,535

)

Total assets, net of depreciation and amortization:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

 

3,948,971

 

 

 

 

 

 

10,603,863

 

 

 

14,552,834

 

International

 

 

410,666

 

 

 

 

 

 

1,013

 

 

 

411,679

 

Capital expenditures

 

 

26,589

 

 

 

 

 

 

12,412

 

 

 

39,001

 

  

 

(1)

All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies.

 

(2)

General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.  Marketing and selling expenses are allocated to our individual reportable segments.

 

(3)

Depreciation and amortization is reflected in cost of goods sold ($99,963 for the year ended December 31, 2015), research and development ($10,617 for the year ended December 31, 2015), and selling, general and administrative expenses ($460,839 for the year ended December 31, 2015).

 

(4)

Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.

 

(5)

Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

 

(6)

Amount of contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect.  See Note 1(a).